Cytosorbents (NASDAQ:CTSO) Issues Earnings Results

Cytosorbents (NASDAQ:CTSO) released its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.73, Zacks reports. Cytosorbents had a negative return on equity of 431.65% and a negative net margin of 48.94%.The firm had revenue of $9.63 million during the quarter, compared to analysts’ expectations of $9.38 million.

Here are the key takeaways from Cytosorbents’ conference call:

• Profitability and cash-burn trends improved: Second-quarter gross margin rose to 73%, adjusted EBITDA loss improved 38% year over year, and operating cash burn fell to approximately $200,000 excluding restructuring payments. Management reiterated its expectation of reaching operating cash-flow breakeven in the second half of 2026.
• Revenue remained essentially flat at $9.6 million: Distributor and strategic-partner revenue increased 16% year over year and direct sales outside Germany rose 9%, offset by continued weakness in Germany and Middle East disruptions. The company plans to add three to five German sales representatives through early 2027.
• DrugSorb-ATR still faces regulatory uncertainty: The FDA previously denied the company’s de novo application because the pivotal STAR-T trial missed its primary endpoint, although management said a new clinical trial is not required. Cytosorbents plans to submit additional mechanistic data and real-world evidence, with separate FDA discussions planned for the ticagrelor and DOAC indications.
• Management highlighted favorable DrugSorb-ATR secondary analyses: In the CABG per-protocol population, the severe-bleeding endpoint achieved a statistically significant win ratio of 1.59, while a composite of severe bleeding or more than one liter of chest-tube blood loss showed a reported 58% relative risk reduction. These analyses may support a renewed FDA submission, though they do not eliminate the prior primary-endpoint miss.
• HemoDefend-BGA represents longer-term strategic optionality rather than current revenue: The universal-plasma technology has completed development and received constructive FDA feedback on a potential clinical pathway, but Cytosorbents does not plan to fund clinical trials from its current resources. Progress depends on government funding, partnerships, licensing, or another strategic transaction.

Cytosorbents Stock Down 2.9%

CTSO traded down $0.21 on Tuesday, hitting $6.80. 16,915 shares of the company were exchanged, compared to its average volume of 7,604. The company has a debt-to-equity ratio of 4.70, a quick ratio of 0.50 and a current ratio of 0.66. The stock’s fifty day moving average is $0.37 and its 200-day moving average is $0.51. The company has a market cap of $428.28 million, a PE ratio of -23.43 and a beta of 1.34. Cytosorbents has a 12 month low of $6.00 and a 12 month high of $20.80.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cytosorbents in a research report on Monday, July 6th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $107.50.

Insider Transactions at Cytosorbents

In other news, CEO Phillip Chan purchased 12,556 shares of Cytosorbents stock in a transaction that occurred on Friday, June 12th. The stock was acquired at an average cost of $8.00 per share, for a total transaction of $100,448.00. Following the purchase, the chief executive officer directly owned 86,704 shares of the company’s stock, valued at $693,632. This trade represents a 16.93% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 7.80% of the company’s stock.

Hedge Funds Weigh In On Cytosorbents

Large investors have recently modified their holdings of the business. Goldman Sachs Group Inc. increased its holdings in shares of Cytosorbents by 149.2% in the first quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock worth $63,000 after purchasing an additional 37,519 shares during the period. Citadel Advisors LLC increased its stake in Cytosorbents by 127.3% during the 3rd quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock valued at $61,000 after purchasing an additional 36,790 shares in the last quarter. CIBC Bancorp USA Inc. bought a new stake in shares of Cytosorbents during the 3rd quarter valued at about $161,000. Vanguard Group Inc. lifted its stake in Cytosorbents by 3.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock worth $2,059,000 after purchasing an additional 79,535 shares in the last quarter. Finally, Avenir Corp increased its holdings in shares of Cytosorbents by 2.9% in the 4th quarter. Avenir Corp now owns 5,230,099 shares of the medical research company’s stock worth $3,343,000 after buying an additional 147,261 shares during the last quarter. Institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.